Global CAR T Cell Therapy Market is expected to register a CAGR of 42.98% during the assessment period of 2020 to 2027, to reach USD 10,415.61 Million by 2027.
The prevalence of cancers is increasing the demand for effective treatment. The number of patients suffering from various types of cancers such as lung, blood, breast, and liver is increasing worldwide. According to the National Cancer Institute, approximately 1,735,350 new cases of cancer were diagnosed, and 609,640 deaths were reported in the US in 2018. Excessive smoking and consumption of alcohol and tobacco are factors increasing the prevalence of cancer across the world. Additionally, obesity is also one of the reasons which may increase the prevalence of cancers. The growth of the obese population is further is expected to increase the demand for CAR T-cell therapy.
According to the World Health Organization (WHO) 2018 fact sheet, excessive consumption of tobacco results in 7 million deaths every year. Lung cancer is the leading cause of death across the globe, i.e., 37%. Thus, the growing number of patients suffering from cancer is expected to increase the demand for CAR T-cell therapy and fuel the growth of the global market during the forecast period.
Global CAR T Cell Therapy Market, by Target Antigen, 2019 (%)
Source: MRFR Analysis
Global CAR T Cell Therapy Market is segmented based on Target Antigen and Application. Based on target antigen, the CD19 segment is held the largest market share in 2019 due to the rising use of biomarkers in CAR T cell therapy. Over the past few years there has been an increase in the number of clinical trials for CD19 antigens. As of January 2018, approximately 50% of about 300 registered CAR-T clinical trials worldwide were either ongoing or complete and were conducted to target CD19 as a biomarker.
Global CAR T Cell Therapy Market, by application, has been segmented into diffuse large B-Cell lymphoma, acute lymphoblastic leukemia, others. Diffuse large B-cell lymphoma is dominating in this segment due to the increasing incidence of diffuse large B-cell lymphoma. According to the Lymphoma Research Foundation, the incidence of NHL has doubled from 1975 to 2013, and an estimated 72,000 new cases were seen in the US in 2016. DLBCL might develop in lymph nodes or other regions like testes, gastrointestinal tract, skin, thyroid, or rather any other organ of the body. Currently, there are two US FDA-approved therapies for large B-cell lymphoma—Yescarta (axicabtagene ciloleucel) and Kymriah (tisagenlecleucel), which is propelling the market growth of this segment.
Global CAR T Cell Therapy Market Share, By Country, 2019 (%)
Source: MRFR Analysis
Global CAR T Cell Therapy Market, based on region, has been divided into the US, Europe, China, and the Rest of the World.
The US dominated the market in 2019 and is likely to continue to command during the assessment period. The growth in this region can be attributed to the increasing cases of cancer. According to the data published by the American Cancer Society, about 1,688,780 new cases were registered in 2017 in the US. Moreover, according to the data published by WHO, cancer is the second-leading cause of death worldwide and was responsible for an estimated 9.6 million deaths in 2018. Furthermore, in the US, there were an estimated 1,762,450 new cancer cases diagnosed and 606,880 deaths due to cancer in 2019. These factors drive the growth of this market.
Europe is the second-largest CAR T cell therapy market during the forecast period. The increase in the occurrences of hematologic cancer, such as leukemia, lymphoma, and multiple myeloma, are the main factors boosting the growth of the market. According to the statistics published by Cancer Research UK, incidence rates for all cancers are projected to rise by 2% in the UK between 2014 and 2035 to 742 cases per 100,000 people by 2035. According to statistics published by WHO, more than 56,000 new cases of cancer were diagnosed in Switzerland in 2018.
China is expected to witness the highest market growth potential over the forecast period due to the developing healthcare infrastructure and increasing disposable income. The rise in the improved healthcare infrastructure promises a high-level of research in the region. Moreover, the increase in the setups of research & development centers and the inclination of top companies toward the developing countries boost the growth of the market in this country. For instance, in September 2018, Novartis AG signed an exclusive marketing agreement with Cellular Biomedicines to manufacture its CAR-T therapy Kymriah in China. This agreement is expected to enhance the company’s market presence in China.
The CAR T Cell Therapy Market in the rest of the world is growing due to the presence of major market player, which is likely to boost the market growth during the forecast period. Moreover, in recent years, major market players have been receiving regulatory approval for their products. For instance, in September 2018, Novartis AG received regulatory approval from Health Canada for Kymriah (tisagenlecleucel/ CTL019), the first CAR-T therapy. This product launch was aimed to strengthen the company’s position in the Canadian market. Such factors are anticipated to fuel the growth of the CAR-T cell therapy market during the forecast period.
The Prominent Market Players are Pfizer (US), Kite Pharma (US), Novartis (Switzerland), Cellectis (Switzerland) and Juno Therapeutics (US).
Some of the key strategies followed by market players were FDA approvals, joint ventures, acquisitions, expansions, and collaborations.
Global CAR T Cell Therapy Market, By Target Antigen
Global CAR T Cell Therapy Market, By Application
Global CAR T Cell Therapy Market, By Region
Available Additional Customizations
Frequently Asked Questions (FAQ) :
CAR T Cell Therapy Market is expected to rise to a valuation of USD 10,415.61 Million by 2027.
The global market is expected to exhibit a strong 42.98% CAGR over the forecast period from 2019 to 2025.
The growing prevalence of cancer and the growing support for the development of effective therapies against cancer is the major driver for the CAR T cell therapy market.
The U.S. holds an overwhelming majority in the global market and is likely to remain the dominant regional market over the forecast period.
Leading players in the CAR T cell therapy market include Novartis, Pfizer, Juno Therapeutics, Kite Pharma, Autolus Therapeutics plc, CARsgen Therapeutics, Cellectis, and Sorrento Therapeutics, among others.
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.